Stocks dropped after Donald Trump ordered that U.S. companies find alternatives to their operations in China.US Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
President Trump again rips into Federal Reserve Chairman Jerome Powell, comparing him to Chinese President Xi Jinping.Politicsread more
Powell repeats his pledge to keep the economic expansion going while acknowledging that tariffs and other factors are causing growth to slow.The Fedread more
Trump is meeting with his top trade advisors at the White House amid a slew of tweets that rocked financial markets Friday morning.Marketsread more
The Koch brothers financed one of the most influential political networks in the modern era. The sprawling political empire includes conservative and libertarian nonprofits...Politicsread more
The two American car companies are among the top exporters of U.S.-produced vehicles to China along with BMW and Daimler/Mercedes-Benz, according to industry data obtained by...Autosread more
China says the new tariffs will begin Sept. 1 and Dec. 15. That's when President Trump's latest tariffs on Chinese goods are to take effect.Marketsread more
The dollar fell on Friday following a speech from Federal Reserve Chair Jerome Powell and after President Donald Trump ordered U.S. companies to find alternatives to their...Currenciesread more
On Tuesday, Walmart filed suit against Tesla alleging its solar panels had caused fires in seven of its stores.Technologyread more
Amazon shows numerous listings for toys and medications that lack the proper health risks to children, as well as sleeping mats previously banned by the FDA, according to a...Technologyread more
Shares of companies developing CRISPR-based therapies slid Monday after STAT News reported two new studies showed edited cells might cause cancer.
Gene editing tool CRISPR-Cas9 has been hailed as a breakthrough that could allow scientists to treat and possibly even cure genetic diseases. In two studies published Monday in the journal Nature Medicine, researchers found editing cells' genomes with the technique might increase the risk of cancer. Those edited cells are those ones that are intended to treat diseases.
The new research could pose a major setback to the treatment. STAT's report on the findings sent some biotech stocks tumbling Monday.
Shares of CRISPR Therapeutics tanked nearly 13 percent, shares of Editas Medicine dropped nearly 8 percent, shares of Intellia Therapeutics fell nearly 10 percent, while shares of Sangamo Therapeutics shed more than 5 percent.
"We do not believe the theoretical risks described in these papers apply to CRISPR Therapeutics' programs," the company said in a statement to CNBC. "We apply CRISPR for gene disruption or high-efficiency gene correction, neither of which are the focus of these reports. In any case, we seek to evaluate all potential risks carefully and assess thoroughly as we advance our programs to the clinic."
Intellia Therapeutics said in a statement it has "observed no signs of this type of toxicity or cells transforming into cancer or tumors in Intellia's in vivo and ex vivo programs."
Lukas Dow, a cancer researcher who uses CRISPR at Weill Cornell Medicine, told CNBC it's "definitely worth paying attention to these effects, but a long way from a deal-breaker."
The papers focused on a gene that encodes for a protein called p53 that's important for tumor suppression, and one of the studies, from the Karolinska Institutet in Sweden, suggested "p53 inhibition may improve the efficiency of genome editing" in certain cells, and that "p53 function should be monitored when developing cell-based therapies utilizing CRISPR-Cas9."
In response, a spokeswoman for Editas said in a statement that "p53 induction in response to DNA damage is a normal and expected response to DNA damage," and that inhibiting p53 could lead to "the accumulation of unwanted mutations from non-CRISPR mechanisms."
"Thus, for making medicines," the statement from Editas concluded, "we do not believe p53 suppression is appropriate or needed to achieve high levels of gene correction."
Editas didn't respond to additional questions.